Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Suppressor of fused homolog (SUFU)
- Target
- SUFU
- Molecular classification
- Signaling pathway regulator, Tumor suppressor, Transcriptional repressor complex component, Scaffold/adapter protein
01
Overview
Suppressor of fused homolog (SUFU) is a protein that acts as a central negative regulator within the Hedgehog signaling pathway by binding and inhibiting the activity of Gli transcription factors, preventing their nuclear accumulation and transcriptional activation of Hedgehog target genes. SUFU's regulatory influence is crucial for normal embryonic development and the suppression of inappropriate cell proliferation; mutations or loss of SUFU function are linked to cancer predilection (notably medulloblastoma and basal cell carcinomas) and disorders of embryogenesis. SUFU exerts its tumor suppressor activity by tethering Gli proteins in the cytoplasm, promoting repressor forms of Gli, and recruiting transcriptional co-repressors in the nucleus. While SUFU itself is not currently a direct drug target, modulation of the HH pathway through upstream effectors indirectly relies on SUFU regulation for their therapeutic efficacy.
- Other names
- SufuSuppressor of FusedSUFU protein
02
Mechanism of action
Hedgehog pathway inhibitors block ligand binding or Smoothened activation, dampening pathway activity where SUFU acts as a downstream effector.
03
Biological functions
Signal transductionCell differentiation and developmentNegative regulation of Gli transcription factorsTumor suppressionRegulator of cell proliferation
04
Disease associations
Cancer (especially medulloblastoma, basal cell carcinoma, and other cancers involving aberrant HH signaling)Congenital disorders (e.g., holoprosencephaly, Greig cephalopolysyndactyly syndrome, basal cell nevus syndrome)Other: potential role in developmental abnormalities
05
Safety considerations
Therapeutic targeting may risk off-target effects on normal developmental and homeostatic processes, as HH signaling is vital for many tissuesSUFU mutation is associated with predisposition to cancers and congenital dysmorphisms
06
Interacting drugs
vismodegib
1 more in the full profile.
07
Biomarkers
Reduced SUFU expression or loss-of-function mutations can serve as biomarkers for medulloblastoma risk and Hedgehog-driven cancersSUFU genetic status may help in patient selection for Hedgehog pathway inhibitor therapies
Beyond the preview
Go deeper on Suppressor of fused homolog (SUFU).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suppressor of fused homolog (SUFU).